US EditionIOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
NEW YORK, UNITED STATES, JUL 8 – Iovance allegedly misled investors about its ability to grow revenue and patient demand, causing a 44% stock price drop in one day, according to the lawsuit.
- A class action lawsuit was filed against Iovance Biotherapeutics, Inc. seeking to recover losses for investors affected from May 9, 2024, to May 8, 2025.
- The lawsuit stems from alleged securities fraud where defendants made misleading statements and concealed problems related to treatment centers and patient identification.
- In early 2024, Iovance introduced Amtagvi for melanoma patients but encountered challenges with treatment delays and patient selection, which negatively impacted their revenue.
- Iovance's stock price dropped from $3.17 on May 8, 2025, to $1.75 on May 9, 2025, a 44.8% decline reflecting negative market reaction.
- Individuals who incurred losses related to Iovance have until mid-July 2025 to file a motion seeking designation as lead plaintiff in the ongoing case before the Northern District of California to recover damages.
19 Articles
19 Articles
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options
IOVA NOTICE: Iovance Biotherapeutics Shareholders are Notified of the Pending Class Action Lawsuit -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before the July 14, 2025 securities fraud class action deadline....
Chatham Star Tribune
IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, July 7, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of…
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company")...
Coverage Details
Bias Distribution
- 57% of the sources are Center
To view factuality data please Upgrade to Premium
